BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 11228364)

  • 1. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells.
    Conway MA; Madrigal-Estebas L; McClean S; Brayden DJ; Mills KH
    Vaccine; 2001 Feb; 19(15-16):1940-50. PubMed ID: 11228364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres.
    Shahin R; Leef M; Eldridge J; Hudson M; Gilley R
    Infect Immun; 1995 Apr; 63(4):1195-200. PubMed ID: 7890372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mice are protected against Bordetella pertussis infection by intra-nasal immunization with filamentous haemagglutinin.
    Cahill ES; O'Hagan DT; Illum L; Redhead K
    FEMS Microbiol Lett; 1993 Mar; 107(2-3):211-6. PubMed ID: 8472903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles.
    Cahill ES; O'Hagan DT; Illum L; Barnard A; Mills KH; Redhead K
    Vaccine; 1995 Apr; 13(5):455-62. PubMed ID: 7639014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
    Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
    Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P.69 and FHA.
    Roberts M; Cropley I; Chatfield S; Dougan G
    Vaccine; 1993; 11(8):866-72. PubMed ID: 8356847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bordetella pertussis filamentous hemagglutinin: evaluation as a protective antigen and colonization factor in a mouse respiratory infection model.
    Kimura A; Mountzouros KT; Relman DA; Falkow S; Cowell JL
    Infect Immun; 1990 Jan; 58(1):7-16. PubMed ID: 2294058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies.
    Polewicz M; Gracia A; Garlapati S; van Kessel J; Strom S; Halperin SA; Hancock RE; Potter AA; Babiuk LA; Gerdts V
    Vaccine; 2013 Jun; 31(31):3148-55. PubMed ID: 23684829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective antigens of Bordetella pertussis mouse-protection test against intracerebral and aerosol challenge of B. pertussis.
    Sato H; Sato Y
    Dev Biol Stand; 1985; 61():461-7. PubMed ID: 2872127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative diphtheria, tetanus and whooping cough immunization schedule to evoke a Th2 tetanus and a Th1 pertussis immune response.
    Lavigne MV; Castro M; Andino J; Manghi M
    Microbes Infect; 2004 Apr; 6(5):481-4. PubMed ID: 15109963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of adsorption of acellular pertussis antigens onto different aluminium salts on the protective activity in an intranasal murine model of Bordetella pertussis infection.
    Denoƫl P; Poolman J; Carletti G; Veitch K
    Vaccine; 2002 Jun; 20(19-20):2551-5. PubMed ID: 12057612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PLGA nano/micro particles encapsulated with pertussis toxoid (PTd) enhances Th1/Th17 immune response in a murine model.
    Li P; Asokanathan C; Liu F; Khaing KK; Kmiec D; Wei X; Song B; Xing D; Kong D
    Int J Pharm; 2016 Nov; 513(1-2):183-190. PubMed ID: 27586408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Th1/Th2 cell dichotomy in acquired immunity to Bordetella pertussis: variables in the in vivo priming and in vitro cytokine detection techniques affect the classification of T-cell subsets as Th1, Th2 or Th0.
    Barnard A; Mahon BP; Watkins J; Redhead K; Mills KH
    Immunology; 1996 Mar; 87(3):372-80. PubMed ID: 8778021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis.
    Garlapati S; Eng NF; Kiros TG; Kindrachuk J; Mutwiri GK; Hancock RE; Halperin SA; Potter AA; Babiuk LA; Gerdts V
    Vaccine; 2011 Sep; 29(38):6540-8. PubMed ID: 21771625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reciprocal protective immunity against Bordetella pertussis and Bordetella parapertussis in a murine model of respiratory infection.
    Watanabe M; Nagai M
    Infect Immun; 2001 Nov; 69(11):6981-6. PubMed ID: 11598073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of a three-component acellular pertussis vaccine administered at birth.
    Belloni C; De Silvestri A; Tinelli C; Avanzini MA; Marconi M; Strano F; Rondini G; Chirico G
    Pediatrics; 2003 May; 111(5 Pt 1):1042-5. PubMed ID: 12728086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cellular immune response to Bordetella pertussis in two children with whooping cough.
    Hafler JP; Pohl-Koppe A
    Eur J Med Res; 1998 Nov; 3(11):523-6. PubMed ID: 9810032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection.
    Jones DH; McBride BW; Thornton C; O'Hagan DT; Robinson A; Farrar GH
    Infect Immun; 1996 Feb; 64(2):489-94. PubMed ID: 8550197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.
    Ryan EJ; McNeela E; Murphy GA; Stewart H; O'hagan D; Pizza M; Rappuoli R; Mills KH
    Infect Immun; 1999 Dec; 67(12):6270-80. PubMed ID: 10569737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.